COVID 19 vaccine - Oravax Medical
Alternative Names: Oral COVID-19 vaccine - Oravax MedicalLatest Information Update: 28 Jan 2025
At a glance
- Originator Oramed Pharmaceuticals; Premas Biotech
- Developer Oravax Medical
- Class COVID-19 vaccines; Peptide vaccines; Protein vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for phase-I development in COVID-2019-infections(Prevention) in South Africa (PO, Capsule)
- 07 Oct 2022 Preliminary immunogenicity data from a phase I trial in Covid-2019 infections (Prevention) were released by OraVax Medical
- 29 Dec 2021 Vietnam's Ministry of Health approves advanced stage clinical trials of oral COVID-19 vaccine